Firstly, in the AD mouse model, subcutaneous administration of EVs derived from AD-MSCs in mice can reduce the levels of inflammatory cytokines and IgE including IL-4, IL-5, IL-13, TNF-α, IFN-γ, IL-17, and TSLP in skin lesion. This evidence concerns the gene IL4 and Alzheimer disease.